Dr Charles Harrington

Dr Charles Harrington
Dr Charles Harrington

Dr Charles Harrington

BSc (Hons) (Glasgow, 1977); PhD (Glasgow, 1980)

Senior Research Fellow


Liberty Building, Institute of Medical Sciences, Foresterhill Road, Aberdeen AB25 2ZP United Kingdom


Charlie Harrington graduated in Microbiology from Glasgow University where he developed an interest in chemical microbiology and the study of microbial cell walls. He completed his PhD working with Dr Julia Douglas on cell wall synthesis in yeast and followed with a one-year NIH-funded Fellowship with Dr Wilf Arnold in Kansas City, Missouri studying enzymes within the yeast cell envelope. After this, Charlie joined Professor Sir James Baddiley in the Department of Biochemistry at the University of Cambridge as a Research Fellow, where he spent four years investigating the synthesis of bacterial cell wall polymers. Dr Harrington then spent over two years at Murex Medical Research Ltd., Cambridge, developing diagnostic tests for microbial diseases, including methicillin-resistant Staphylococcus aureus and sexually transmitted diseases. This combined monoclonal antibody technology with his knowledge of the microbial cell surface.

In 1988, he joined Claude Wischik working at the Medical Research Council’s Laboratory of Molecular Biology. Working in the Cambridge Brain Bank Laboratory over a period of 10 years. During this time, Wischik, Harrington and colleagues developed an assay for screening agents having the potential to prevent the tau pathology that is the hallmark of Alzheimer’s disease. Charlie moved with Professor Wischik, in 1998, to the University of Aberdeen, where he was appointed as a Senior Research Fellow.

The Alzheimer's research was translated to the clinic, through a spin-out company, TauRx Therapeutics, who are conducting phase 3 trials of hydromethylthionine.  Dr Harrington is Chief Scientific Officer for TauRx Therapeutics Ltd responsible for the non-clinical activities of the company.


  • BSc (Hons) Microbiology 
    1977 - University of Glasgow 
  • PhD Microbiology 
    1980 - University of Glasgow 

Latest Publications

View My Publications


Research Overview

Dr Harrington has research interests in the neurodegenerative diseases and, in particular, Alzheimer’s disease. His main focus has been on the biology of tau protein in aging and in Alzheimer’s disease. Dr Harrington’s research is aimed at diseases that are characterised by protein aggregation and methods by which these processes might be prevented.


Page 5 of 8 Results 41 to 50 of 78

  • Complex Disposition of Methylthioninium Redox Forms Determines Efficacy in Tau Aggregation Inhibitor Therapy for Alzheimer's Disease

    Baddeley, T. C., McCaffrey, J., Storey, J. M. D., Cheung, J. K. S., Melis, V., Horsley, D., Harrington, C. R., Wischik, C. M.
    Journal of Pharmacology and Experimental Therapeutics, vol. 352, no. 1, pp. 110-118
    Contributions to Journals: Articles
  • Tau-aggregation inhibitor therapy for Alzheimer's disease

    Wischik, C. M., Harrington, C. R., Storey, J. M. D.
    Biochemical Pharmacology, vol. 88, no. 4, pp. 529-539
    Contributions to Journals: Articles
  • TauRx global phase 3 trial in Alzheimer's disease with tau aggregation inhibitor LMTX

    Wischik, C. M., Harrington, C. R., Storey, J. M. D.
    13th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy, pp. S26
    Contributions to Journals: Abstracts
  • Calcyclin binding protein and Siah-1 interacting protein in Alzheimer's disease pathology: neuronal localization and possible function

    Wasik, U., Schneider, G., Mietelska-Porowska, A., Mazurkiewicz, M., Fabczak, H., Weis, S., Zabke, C., Harrington, C. R., Filipek, A., Niewiadomska, G.
    Neurobiology of Aging, vol. 34, no. 5, pp. 1380-1388
    Contributions to Journals: Articles
  • New phenothiazine diaminium compounds are tau protein aggregation inhibitors, useful to treat e.g. Alzheimer's disease, Pick's disease, progressive supranuclear palsy, frontotemporal dementia and frontotemporal lobar degeneration syndromes

    Baddeley, T., Clunas, S., Harrington, C. R., Horsley, D., Ishaq, A., Khan, K., Loh, Y. S., Marshall, C., Rickard, J. E., Simpson, M., Sinclair, J. P., Storey, J. M. D., Williamson, C., Wischik, C. M., Wood, B. A.
    Patents: Patents
  • The molecular pathology of Alzheimer's disease

    Harrington, C. R.
    Neuroimaging Clinics of North America, vol. 22, no. 1, pp. 11-22
    Contributions to Journals: Literature Reviews
  • 3,7-diamino-10H-phenothiazine salts and their use: WO2007110627

    Wischik, C. M., Rickard, J. E., Harrington, C. R., Horsley, D., Storey, J. M. D., Marshall, C., Sinclair, J. P., Baddeley, T.
    Patents: Patents
  • Stripline resonator and preamplifier for preclinical magnetic resonance imaging at 4.7 T

    Lavdas, I., Seton, H., Harrington, C. R., Wischik, C. M.
    Magnetic Resonance Materials in Physics, Biology and Medicine, vol. 24, no. 6, pp. 331-337
    Contributions to Journals: Articles
  • 3,6-Disubstituted xanthylium salts

    Clunas, S., Storey, J. M. D., Horsley, D., Rickard, J. E., Harrington, C. R., Wischik, C. M.
    Patents: Patents
  • Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (MTC): methods of treatment of a tauopathy condition comprising the use of thioninium compounds

    Wischik, C. M., Rickard, J. E., Harrington, C. R., Horsley, D., Storey, J. M. D., Marshall, C., Sinclair, J. P.
    Patents: Patents


Chapters in Books, Reports and Conference Proceedings

Contributions to Journals